Temel Tirkes MD, Presenter: Nothing to Disclose

Tariq Arshad Hameed MD, Abstract Co-Author: Research Grant, Koninklijke Philips NV

Fatih Akisik MD, Abstract Co-Author: Nothing to Disclose

Concepts in oncologic treatment have radically changed in past 10 years. Targeted therapies are designed with entirely new concept of inducing apopytosis compared to traditional cytotoxic drugs. Imaging modalities allow monitoring the changes in tumor size, morphology and metabolism during the course of therapy. Several criteria based on size, morphology or functional change of the tumor have been developed to analyze tumor response observed during the course of the therapy, in order to provide an early assessment of the treatment.  

This is a case-based review of disease and therapy specific aspects of emerging response evaluation criteria by CT, MRI and FDG-PET. Focus is on what the radiologist needs to know when interpreting CT/MRI or CT-PET on oncologic patients who are being treated with new targeted therapies.  1. Review the most common targeted therapies and mechanism of action 2. New response criteria specifically designed for targeted therapies in clinical trials Choi’s Response Criteria PERCIST mRECIST (for Hepatocellulaar Carcinoma) irRC (for melanoma) Cheson criteria (for Lymphoma) 3. Quantitative measurements and post-processing 4. Clinical summaries and case based images 5. Comparisons with traditional criteria; RECIST and WHO  

http://abstract.rsna.org/uploads/2014/14003902/14003902_3eqf.pdf

Tirkes, T, Hameed, T, Akisik, F, New Tumor Response Criteria in the Era of Targeted Therapies in Oncology.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14003902.html